BC Innovations | Oct 24, 2019
Distillery Therapeutics

Combined PTP-1B and PTPN2 inhibition for weight loss in obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Combined inhibition of PTP-1B and PTPN2, which regulate leptin and insulin signaling, could promote weight loss in obese patients. In mice with high fat diet-induced obesity, knockout of both targets...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Innovations | Aug 16, 2017
Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies suggest inhibiting PTPN2 could help sensitize tumors to anti- PD-1 mAbs. In two mouse models of melanoma and a mouse model of colorectal cancer treated with an anti-PD-1 mAb, tumor-specific knockout...
BioCentury | Mar 10, 2014
Product Development

Inactivating warheads

Targanox Inc. believes it has found a way to access some previously undruggable enzyme targets by taking advantage of changes in the oxidation state of cysteine residues to trap the enzymes in an inactive configuration....
BioCentury | Mar 26, 2007
Product Development

Metabolic Milestones

The increasing prevalence of metabolic diseases has become a growing concern as studies continue to draw links between them and a wide array of comorbidities. As new targets and pathways come to light, the race...
Items per page:
1 - 5 of 5